SCHEMBL22337384

SCHEMBL22337384

CCc1cc(C)c(OCCN2CCOCC2)c(C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
POLB P06746 1/20 0.55
NPC1 O15118 1/20 0.52
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
ALDH1A1 P00352 4/20 0.47
HTR1A P08908 1/20 0.47
KDM4E B2RXH2 1/20 0.46
P2RY12 Q9H244 1/20 0.46
CYP1A2 P05177 1/20 0.46
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
HTR2A P28223 1/20 0.46
MAPK1 P28482 1/20 0.46
SCN1A P35498 1/20 0.46
HTR2B P41595 1/20 0.46
KCNH2 Q12809 1/20 0.46
SCN2A Q99250 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14578262 0.90 SYK (0.59) SYKMEN1KMT2APOLBNPC1
SCHEMBL14577958 0.90 POLB (0.59) SYKMEN1KMT2APOLBNPC1
SCHEMBL19227456 0.86 POLB (0.71) SYKMEN1KMT2APOLBNPC1
SCHEMBL3426969 0.84 SYK (0.59) SYKMEN1KMT2APOLBNPC1
SCHEMBL17537447 0.84 SYK (0.59) SYKMEN1KMT2APOLBNPC1
SCHEMBL13766288 0.82 POLB (0.58) SYKMEN1KMT2APOLBNPC1
SCHEMBL19224090 0.81 MEN1 (0.57) SYKMEN1KMT2APOLBNPC1
SCHEMBL348153 0.80 MEN1 (0.59) SYKMEN1KMT2APOLBNPC1
SCHEMBL13534008 0.80 POLB (0.56) SYKMEN1KMT2APOLBNPC1
SCHEMBL7988768 0.79 MEN1 (0.68) SYKMEN1KMT2APOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220133736-A1 USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2022-05-05 US disclosed
US-20200253981-A1 USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220133736-A1 USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS SIK2, SIK1, SIK3 SYK 1233/4885MEN1 4515/4885KMT2A 2339/4885
US-20200253981-A1 USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS SIK2, SIK1, SIK3 SYK 1233/4885MEN1 4515/4885KMT2A 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.